These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 28215414)

  • 41. One-year outcome of patients with diabetes mellitus after percutaneous coronary intervention with three different revascularization strategies: results from the Diabetic Argentina Registry (DEAR).
    Mieres J; Fernandez-Pereira C; Risau G; Solorzano L; Pauletto R; Rodriguez-Granillo AM; Rubilar B; Stella P; Rodriguez AE
    Cardiovasc Revasc Med; 2012; 13(5):265-71. PubMed ID: 22796496
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cardiac events after non-cardiac surgery in patients with previous coronary intervention in the drug-eluting stent era.
    Bolad IA; Alqaqa'a A; Khan B; Srivastav SK; von der Lohe E; Sadanandan S; Breall JA
    J Invasive Cardiol; 2011 Jul; 23(7):283-6. PubMed ID: 21725123
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent).
    Ellis SG; Stone GW; Cox DA; Hermiller J; O'Shaughnessy C; Mann T; Turco M; Caputo R; Bergin PJ; Bowman TS; Baim DS;
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1248-59. PubMed ID: 20129552
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Randomized Comparison of Xience V and Multi-Link Vision Coronary Stents in the Same Multivessel Patient With Chronic Kidney Disease (RENAL-DES) Study.
    Tomai F; Ribichini F; De Luca L; Petrolini A; Ghini AS; Weltert L; Spaccarotella C; Proietti I; Trani C; Nudi F; Pighi M; Vassanelli C
    Circulation; 2014 Mar; 129(10):1104-12. PubMed ID: 24357403
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term clinical and economic analysis of the Endeavor drug-eluting stent versus the Driver bare-metal stent: 4-year results from the ENDEAVOR II trial (Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Medtronic AVE ABT-578 Eluting Driver Coronary Stent in De Novo Native Coronary Artery Lesions).
    Eisenstein EL; Wijns W; Fajadet J; Mauri L; Edwards R; Cowper PA; Kong DF; Anstrom KJ
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1178-87. PubMed ID: 20129543
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.
    Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K
    Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-Term outcome of drug-eluting stents compared with bare metal stents in ST-segment elevation myocardial infarction: results of the paclitaxel- or sirolimus-eluting stent versus bare metal stent in Primary Angioplasty (PASEO) Randomized Trial.
    Di Lorenzo E; Sauro R; Varricchio A; Carbone G; Cortese G; Capasso M; Lanzillo T; Manganelli F; Mariello C; Siano F; Pagliuca MR; Stanco G; Rosato G; De Luca G
    Circulation; 2009 Sep; 120(11):964-72. PubMed ID: 19720939
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Drug-eluting or bare-metal stenting in patients with diabetes mellitus: results from the Massachusetts Data Analysis Center Registry.
    Garg P; Normand SL; Silbaugh TS; Wolf RE; Zelevinsky K; Lovett A; Varma MR; Zhou Z; Mauri L
    Circulation; 2008 Nov; 118(22):2277-85, 7p following 2285. PubMed ID: 19001019
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial.
    Räber L; Kelbæk H; Ostojic M; Baumbach A; Heg D; Tüller D; von Birgelen C; Roffi M; Moschovitis A; Khattab AA; Wenaweser P; Bonvini R; Pedrazzini G; Kornowski R; Weber K; Trelle S; Lüscher TF; Taniwaki M; Matter CM; Meier B; Jüni P; Windecker S;
    JAMA; 2012 Aug; 308(8):777-87. PubMed ID: 22910755
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?: A Pre-Specified Analysis From the ZEUS Trial.
    Ariotti S; Adamo M; Costa F; Patialiakas A; Briguori C; Thury A; Colangelo S; Campo G; Tebaldi M; Ungi I; Tondi S; Roffi M; Menozzi A; de Cesare N; Garbo R; Meliga E; Testa L; Gabriel HM; Ferlini M; Vranckx P; Valgimigli M;
    JACC Cardiovasc Interv; 2016 Mar; 9(5):426-36. PubMed ID: 26965932
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry).
    Nienaber CA; Akin I; Schneider S; Senges J; Fetsch T; Tebbe U; Willich SN; Stumpf J; Sabin GV; Silber S; Richardt G; Kuck KH;
    Am J Cardiol; 2009 Nov; 104(10):1362-9. PubMed ID: 19892051
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term clinical outcomes in patients treated with drug-eluting compared to bare-metal stents for the treatment of transplant coronary artery disease.
    Lee MS; Yang T; Kandzari D; Mahmud E; Liao H; Kirtane A
    Catheter Cardiovasc Interv; 2012 Oct; 80(4):533-8. PubMed ID: 21953766
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: main results of the Basel Stent Kosten-Effektivitäts Trial-PROspective Validation Examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome trial.
    Kaiser C; Galatius S; Jeger R; Gilgen N; Skov Jensen J; Naber C; Alber H; Wanitschek M; Eberli F; Kurz DJ; Pedrazzini G; Moccetti T; Rickli H; Weilenmann D; Vuillomenet A; Steiner M; Von Felten S; Vogt DR; Wadt Hansen K; Rickenbacher P; Conen D; Müller C; Buser P; Hoffmann A; Pfisterer M;
    Circulation; 2015 Jan; 131(1):74-81. PubMed ID: 25411159
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term effects of drug-eluting stents versus bare metal stents on patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: outcomes of 3-year clinical follow-up.
    Wang CH; Fang Q; Zhang SY; Shen ZJ; Fan ZJ; Jin XF; Zeng Y; Liu ZY; Xie HZ; Yang M
    Chin Med J (Engl); 2012 Aug; 125(16):2803-6. PubMed ID: 22932070
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Can intravascular ultrasound guidance modify the efficacy of drug-eluting stent over bare-metal stent in an aorto-ostial lesion?
    Okabe T; Kawamura A; Maekawa Y; Anzai T; Iwanaga S; Yoshikawa T; Ogawa S
    Cardiovasc Revasc Med; 2011; 12(2):105-10. PubMed ID: 21421189
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical outcomes following percutaneous coronary intervention with drug-eluting stents versus bare metal stents in patients on chronic hemodialysis.
    Meliga E; De Benedictis M; Gagnor A; Conrotto F; Novara M; Scrocca I; Varbella F; Marra S; Conte MR
    J Interv Cardiol; 2013 Aug; 26(4):351-8. PubMed ID: 23795563
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Drug-eluting stents in patients on chronic hemodialysis: paclitaxel-eluting stents vs. limus-eluting stents.
    Sardi GL; Loh JP; Torguson R; Laynez-Carnicero A; Kitabata H; Xue Z; Satler LF; Pichard AD; Waksman R
    Cardiovasc Revasc Med; 2014 Mar; 15(2):86-91. PubMed ID: 24684759
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical presentation and outcomes of coronary in-stent restenosis across 3-stent generations.
    Magalhaes MA; Minha S; Chen F; Torguson R; Omar AF; Loh JP; Escarcega RO; Lipinski MJ; Baker NC; Kitabata H; Ota H; Suddath WO; Satler LF; Pichard AD; Waksman R
    Circ Cardiovasc Interv; 2014 Dec; 7(6):768-76. PubMed ID: 25466551
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical outcomes following drug-eluting versus bare metal stent implantation for lesion subsets excluded from pivotal clinical trials: findings from the GHOST Study (Guthrie Health System Off-Label StenT Study).
    Harjai KJ; Orshaw P; Shenoy C; Acharji S; Sporn D; Aboufares A; Stapleton D
    J Interv Cardiol; 2008 Aug; 21(4):315-24. PubMed ID: 18754967
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A prospective randomized trial of everolimus-eluting stents versus bare-metal stents in octogenarians: the XIMA Trial (Xience or Vision Stents for the Management of Angina in the Elderly).
    de Belder A; de la Torre Hernandez JM; Lopez-Palop R; O'Kane P; Hernandez Hernandez F; Strange J; Gimeno F; Cotton J; Diaz Fernandez JF; Carrillo Saez P; Thomas M; Pinar E; Curzen N; Baz JA; Cooter N; Lozano I; Skipper N; Robinson D; Hildick-Smith D;
    J Am Coll Cardiol; 2014 Apr; 63(14):1371-5. PubMed ID: 24216285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.